Third, we propose that ATM-MT bladder cancer patients may benefit from the combined application of ICIs and IGF-1R inhibitors, which opens a new approach for clinical treatment, but further experimental confirmation is still needed. Here, IGF1R is linked to urinary bladder cancer.